ALX Oncology Holdings Inc. (ALXO), a clinical-stage biotechnology company, has data readouts scheduled this year for two of its clinical programs, which could determine the future of its therapeutic candidates.
The company is focused on developing highly differentiated medicines that optimise the immune system's ability to fight cancer and fully deliver on the promise of innovative cancer therapies. Its pipeline includes two clinical drug candidates - Evorpacept and ALX2004.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com